Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KOD NASDAQ:SPRY NASDAQ:TRVI NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$42.90+5.0%$36.76$5.00▼$47.84$2.69B2.19895,012 shs102,764 shsSPRYARS Pharmaceuticals$6.21-3.6%$8.54$6.18▼$18.63$614.47M0.951.65 million shs1.92 million shsTRVITrevi Therapeutics$17.68+5.4%$15.89$6.55▼$20.22$2.51B11.74 million shs772,522 shsVERAVera Therapeutics$36.84-0.4%$37.15$19.07▼$56.05$2.65B0.921.36 million shs267,677 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences-4.15%-0.56%+13.09%-11.42%+640.40%SPRYARS Pharmaceuticals-8.00%-16.80%-33.26%-17.86%-64.06%TRVITrevi Therapeutics-12.06%+1.51%-2.56%+14.71%+144.46%VERAVera Therapeutics-3.92%-10.87%+5.41%-7.66%+60.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$42.90+5.0%$36.76$5.00▼$47.84$2.69B2.19895,012 shs102,764 shsSPRYARS Pharmaceuticals$6.21-3.6%$8.54$6.18▼$18.63$614.47M0.951.65 million shs1.92 million shsTRVITrevi Therapeutics$17.68+5.4%$15.89$6.55▼$20.22$2.51B11.74 million shs772,522 shsVERAVera Therapeutics$36.84-0.4%$37.15$19.07▼$56.05$2.65B0.921.36 million shs267,677 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences-4.15%-0.56%+13.09%-11.42%+640.40%SPRYARS Pharmaceuticals-8.00%-16.80%-33.26%-17.86%-64.06%TRVITrevi Therapeutics-12.06%+1.51%-2.56%+14.71%+144.46%VERAVera Therapeutics-3.92%-10.87%+5.41%-7.66%+60.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKODKodiak Sciences 2.63Moderate Buy$42.143.11% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.20337.89% UpsideTRVITrevi Therapeutics 2.92Moderate Buy$24.9148.53% UpsideVERAVera Therapeutics 2.77Moderate Buy$84.58128.67% UpsideCurrent Analyst Ratings BreakdownLatest SPRY, VERA, TRVI, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026TRVITrevi Therapeutics BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$36.007/20/2026TRVITrevi Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $31.007/20/2026TRVITrevi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $24.007/17/2026TRVITrevi Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VERAVera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/10/2026KODKodiak Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026VERAVera Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$73.00 ➝ $78.007/8/2026VERAVera Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $76.007/8/2026VERAVera Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$125.007/8/2026VERAVera Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$35.00 ➝ $43.007/8/2026VERAVera Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $125.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ASPRYARS Pharmaceuticals$84.28M7.59N/AN/A$1.16 per share5.55TRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$8.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)SPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)VERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)Latest SPRY, VERA, TRVI, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026KODKodiak Sciences-$0.97N/AN/AN/AN/AN/A8/12/2026Q2 2026SPRYARS Pharmaceuticals-$0.4766N/AN/AN/A$31.33 millionN/A8/6/2026Q2 2026TRVITrevi Therapeutics-$0.11N/AN/AN/AN/AN/A8/4/2026Q2 2026VERAVera Therapeutics-$1.60N/AN/AN/A$1.28 millionN/A5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKODKodiak SciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKODKodiak SciencesN/A3.543.54SPRYARS Pharmaceuticals2.794.944.77TRVITrevi TherapeuticsN/A24.7524.75VERAVera Therapeutics0.1513.6413.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKODKodiak Sciences89.06%SPRYARS Pharmaceuticals68.16%TRVITrevi Therapeutics95.76%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipKODKodiak Sciences44.40%SPRYARS Pharmaceuticals33.80%TRVITrevi Therapeutics15.39%VERAVera Therapeutics15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKODKodiak Sciences9062.58 million34.79 millionOptionableSPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableTRVITrevi Therapeutics20141.98 million120.13 millionOptionableVERAVera Therapeutics4071.78 million60.37 millionOptionableSPRY, VERA, TRVI, and KOD HeadlinesRecent News About These CompaniesJ. Safra Sarasin Holding AG Has $524,000 Stake in Vera Therapeutics, Inc. $VERAJuly 16, 2026 | marketbeat.comVera Therapeutics Inc - Ordinary Shares - Class AJuly 13, 2026 | money.usnews.comAnalysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)July 12, 2026 | theglobeandmail.comCandriam S.C.A. Increases Position in Vera Therapeutics, Inc. $VERAJuly 12, 2026 | marketbeat.comVera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets LaunchJuly 11, 2026 | marketbeat.comVera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% RunJuly 10, 2026 | finance.yahoo.comVera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA ApprovalJuly 10, 2026 | finance.yahoo.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 6.8% on Insider SellingJuly 10, 2026 | marketbeat.comQ3 EPS Forecast for Vera Therapeutics Decreased by AnalystJuly 10, 2026 | marketbeat.comMarshall Fordyce Sells 46,250 Shares of Vera Therapeutics (NASDAQ:VERA) StockJuly 10, 2026 | insidertrades.comVera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade)July 9, 2026 | seekingalpha.comVera Therapeutics (NASDAQ:VERA) CEO Sells $1,956,375.00 in StockJuly 9, 2026 | marketbeat.comVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerJuly 9, 2026 | globenewswire.comVera Therapeutics wins FDA nod for closely watched kidney disease drugJuly 8, 2026 | finance.yahoo.comPharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and moreJuly 8, 2026 | statnews.comSFDA grants accelerated approval to Vera Therapeutics' TrutaknaJuly 8, 2026 | finance.yahoo.comWedbush Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceJuly 8, 2026 | marketbeat.comUnder the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDAJuly 7, 2026 | wsj.comFDA approves Vera Therapeutics kidney disease treatmentJuly 7, 2026 | statnews.comSVera Therapeutics wins first FDA approval with kidney disease drugJuly 7, 2026 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026The SpaceX Sell-Off May Be More Than a Market OverreactionBy Jeffrey Neal Johnson | June 24, 2026Rocket Lab's NASA Win Tests Key Support After Sharp PullbackBy Ryan Hasson | June 26, 2026Costco’s Secret Growth Engine May Be Running Out of GasBy Dan Schmidt | June 28, 2026Dividend Increases: From Over 10% Yields to Over 10% Dividend GrowthBy Leo Miller | June 24, 2026SPRY, VERA, TRVI, and KOD Company DescriptionsKodiak Sciences NASDAQ:KOD$42.90 +2.03 (+4.97%) As of 12:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.ARS Pharmaceuticals NASDAQ:SPRY$6.21 -0.23 (-3.57%) As of 12:03 PM Eastern This is a fair market value price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Trevi Therapeutics NASDAQ:TRVI$17.68 +0.91 (+5.40%) As of 12:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Vera Therapeutics NASDAQ:VERA$36.84 -0.15 (-0.41%) As of 12:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Microsoft's AI Bet Could Rewrite AMD's Growth Story Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
